HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis

被引：5
|
作者：
Al-azawi, Dhafir [1 ,3 ]
Leong, Sum [1 ]
Wong, Limy [1 ]
Kay, Elaine [2 ]
Hill, Arnold D. K. [1 ,3 ]
Young, Leonie [3 ]
机构：
[1] Beaumont Hosp, Dept Surg, Dublin 9, Ireland
[2] Beaumont Hosp, Dept Histopathol, Dublin 9, Ireland
[3] Royal Coll Surgeons Ireland, Ctr Mol & Surg Res, Dublin 2, Ireland
来源：
CANCER INVESTIGATION | 2011年 / 29卷 / 05期
关键词：
Breast cancers; Cancer biomarkers; Chemotherapy; EXPRESSION; MUTATIONS; C-ERBB-2; PROTEIN; COEXPRESSION; SURVIVAL; OVEREXPRESSION; AMPLIFICATION; RECEPTOR; IMPACT;
D O I：
10.3109/07357907.2011.584586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
p53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02). p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.
引用
收藏
页码：365 / 369
页数：5
相关论文
共 50 条
  • [1] Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis
    Puskulluoglu, Miroslawa
    Rudzi, Agnieszka
    Pacholczak-Madej, Renata
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (06):
  • [2] IMPLICATIONS OF EXTRACAPSULAR NODAL METASTASES FOR PROGNOSIS IN HER-2 RECEPTOR POSITIVE AND NEGATIVE BREAST CANCERS
    Maksimovic, S.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 36 - 36
  • [3] The epidemiology of Her-2/neu and P53 in breast cancer
    Bernstein, JL
    López-Carrillo, L
    Wang, L
    [J]. SALUD PUBLICA DE MEXICO, 1999, 41 : S114 - S123
  • [4] Her-2 Expression in p53 and Endometrial Cancers compared to Serous Carcinomas
    Kinloch, Marilyn
    Baniak, Nicholas
    Campbell, Katelynn
    Torlakovic, Emina
    Gilks, C. Blake
    [J]. LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 777 - 778
  • [5] Her-2 Expression in p53 and Endometrial Cancers compared to Serous Carcinomas
    Kinloch, Marilyn
    Baniak, Nicholas
    Campbell, Katelynn
    Torlakovic, Emina
    Gilks, C. Blake
    [J]. MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 777 - 778
  • [6] HER-2,P53 and Hormonal Receptors Protein Expression as Predictive Factors in Breast Cancer Prognosis
    Seyed Mohammad Rabiee Hashemi
    Somayeh Rabiee Hashemi
    [J]. Cancer Biology & Medicine, 2008, 5 (06) : 413 - 417
  • [7] Morphological heterogeneity of p53 positive and p53 negative nuclei in breast cancers stratified by clinicopathological variables
    Friedrich, K
    Dimmer, V
    Haroske, G
    Meyer, W
    Theissig, F
    Thieme, B
    Kunze, KD
    [J]. ANALYTICAL CELLULAR PATHOLOGY, 1997, 14 (02): : 111 - 123
  • [8] NUCLEAR P53 IMMUNOREACTION ASSOCIATED WITH POOR PROGNOSIS OF BREAST-CANCER
    IWAYA, K
    TSUDA, H
    HIRAIDE, H
    TAMAKI, K
    TAMAKUMA, S
    FUKUTOMI, T
    MUKAI, K
    HIROHASHI, S
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1991, 82 (07): : 835 - 840
  • [9] Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis
    Albanell, J
    Bellmunt, J
    Molina, R
    Garcia, M
    Caragol, I
    Bermejo, B
    Ribas, A
    Carulla, J
    Gallego, OS
    Espanol, T
    Calvo, LAS
    [J]. ANTICANCER RESEARCH, 1996, 16 (02) : 1027 - 1032
  • [10] p53 and Her-2/neu in juvenile angiofibromas
    Schick, B
    Veldung, B
    Wemmert, S
    Jung, V
    Montenarh, M
    Meese, E
    Urbschat, S
    [J]. ONCOLOGY REPORTS, 2005, 13 (03) : 453 - 457
12345